From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 17,998,609 shares, representing 13.25% for $750.03 million under the buyback announced on December 9, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.5 USD | -0.24% | -2.65% | +33.93% |
06-13 | Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing | MT |
06-11 | Halozyme Therapeutics May Seeks M&A | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.93% | 6.3B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.